12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of patients 12 years of age and older with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine.

Selpercatinib is recommended as an option in patients 12 years and over with:

• Advanced RET fusion positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate), only if systemic treatment is needed after sorafenib tosylate or lenvatinib mesylate
• Advanced RET mutant medullary thyroid cancer, only if systemic treatment is needed after cabozantinib maleate or vandetanib

Selpercatinib is only recommended if Eli Lilly provides it according to the commercial arrangement.

Read NICE technology appraisal guidance